重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合醋氯芬酸缓释片治疗类风湿性关节炎的临床研究

摘要

目的：探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合醋氯芬酸缓释片治疗类风湿性关节炎的临床疗效。方法选择2014年12月至2016年1月本院类风湿性关节炎患者103名，随机分为对照组、实验组，对照组给予重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白25mg，每周注射2次；实验组在注射重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗的基础上再给予口服醋氯芬酸缓释片0.1g，每天两次。4周，8周疗程观察对比患者治疗前和治疗后的晨僵时间、患者关节疼痛VAS评分、患者关节肿胀指数、患者触痛关节指数、日常生活能力，观察患者临床疗效。结果临床研究结果表明4周，8周疗程后实验组的有效率明显高于对照组的有效率。另外，患者膝关节疼痛评分、肿胀指数、触痛指数均较治疗前明显改善，所有比较均有统计学意义P<0.05。结论重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合醋氯芬酸缓释片治疗类风湿性关节炎治疗效果安全可靠，值得在临床上推广。%Objective to investigate clinical effects of recombinant human tumor necrosis factor receptor Ⅱ- antibody fusion protein combined with Aceclofenac sustained-release tablets in treatment of rheumatoid arthritis.Methods choose 103 cases rheumatoid arthritis arthritis patients treated in our hospital from December 2014 to January 2016, randomly divide them into control and experimental group. Control group were treated with recombinant human tumor necrosis factor receptor Ⅱ 25mg, twice injections weekly; and experimental group with oral Aceclofenac sustained-release tablets 0.1g on the basis of recombinant human tumor necrosis factor receptor II, twice a day. After 4 and 8 weeks treating course, observe and compare patients before and after treatment with time of morning stiffness, joint pain VAS score, joint swelling index, joint tenderness index, daily living ability, and observe clinical curative effect of patients. Results clinical results showed effective rate of experimental group was significantly higher than control group after 4 and 8 weeks treating course. Also knee joint pain score, swelling index, tenderness index changed greatly compared with that before treatment, and all comparisons showed statistical significance (P< 0.05).Conclusion recombinant human tumor necrosis factor receptor Ⅱ - antibody fusion protein combined with Aceclofenac sustained-release tablets has safe and reliable effect for rheumatoid arthritis, which is worthy of clinical promotion.